Peer-to-Peer

Shelley Johns, PsyD, joins Physician’s Weekly, for one final installment. She emphasizes the importance of standardized screening for fear of recurrence in breast cancer survivors.

Dr. Shelly Johns joins Physician’s Weekly and explains why a stepped care approach to managing fear of cancer recurrence is recommended.

Shelly Johns, PsyD, clinical psychologist, explains how supportive interventions can improve the quality of life for adults with breast cancer.

Shelly Johns, PsyD, clinical psychologist, emphasizes the importance of physicians routinely addressing fear of cancer recurrence in patient conversations.

The following is a summary of “Lipid Metabolic Reprograming: the Unsung Hero in Breast...

Preeclampsia greatly increases severe maternal morbidity risk. Targeted prenatal monitoring is key, especially for patients with chronic hypertension.

The following is a summary of “Vaginal estrogen use in breast cancer survivors: a systematic...

Study highlights concerns about premature adoption of preeclampsia screening tests, emphasizing the need for clinical utility trials before widespread implementation.

Recent preeclampsia studies have investigated predictors such as placenta location and PAPP-A, in addition to comparing the P/C ratio with 24-hour proteinuria.

The following is a summary of “Role of Negative Affect and Experiential Avoidance in Postsurgical...

The reasons why preeclampsia and other hypertensive disorders impact up to 8% of pregnancies are not fully understood, prompting calls for further research.

Routine screening for patient-reported outcomes may improve access to supportive care services among long-term metastatic breast cancer survivors.

Elevations in biomarkers such as uterine artery pulsatility index and placental growth factor throughout pregnancy indicate preeclampsia risk.

Findings published in Clinical Epigenetics underscore the impact of differentially methylated regions in pregnancy complications, including preeclampsia.

Genomic profiling in the FLEX trial predicted chemotherapy response in HR+, HER2- breast cancer, which could enable tailored treatment plans.

Justin Balko, PharmD, PhD, reviews his session from SABCS 2024 where he discussed the challenges and advancements in immunotherapy for early-stage triple-negative breast cancer (TNBC). Additionally, he discusses the importance of identifying predictive biomarkers to optimize treatment and improve patient quality of life.

Physician’s Weekly spoke with Dr. Otsubo and Dr. Hara about their research and how they anticipate the SDB kit will be applied in clinical settings.

Justin Balko, PharmD, PhD, recently joined Dr. Priyanka Sharma and Dr. Roberto Salgado at the 2024 San Antonio Breast Cancer Symposium to discuss immune biomarkers, including tumor-infiltrating lymphocytes, and their roles.

Dr. Marla Lipsyc-Sharf reviews her recent session at the 2024 SABCS meeting, discussing biopsy approaches and treatment sequencing in metastatic breast cancer.